+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Trelegy Ellipta

  • ID: 4533476
  • Report
  • July 2018
  • Region: Global
  • 30 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Trelegy Ellipta ([fluticasone furoate + vilanterol + umeclidinium bromide]; GlaxoSmithKline) is a fixed triple combination inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy. The product contains the same ICS/LABA components as Breo ([fluticasone furoate + vilanterol]; GlaxoSmithKline/Innoviva), plus a LAMA component, umeclidinium bromide.

GlaxoSmithKline received approval for Trelegy Ellipta in chronic obstructive pulmonary disease in Q3 2017, and is currently evaluating the drug in asthma patients whose symptoms are inadequately controlled by ICS/LABA therapies.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Trelegy Ellipta: Chronic obstructive pulmonary disease (COPD)
Trelegy Ellipta: Asthma

LIST OF FIGURES
Figure 1: Trelegy Ellipta for COPD – SWOT analysis
Figure 2: The authors drug assessment summary of Trelegy Ellipta for COPD
Figure 3: The authors drug assessment summary of Trelegy Ellipta for COPD
Figure 4: Trelegy Ellipta sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Trelegy Ellipta for asthma – SWOT analysis
Figure 6: The authors drug assessment summary of Trelegy Ellipta in asthma
Figure 7: The authors drug assessment summary of Trelegy Ellipta in asthma
Figure 8: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Trelegy Ellipta drug profile
Table 2: Trelegy Ellipta Phase III data in COPD
Table 3: Trelegy Ellipta Phase III trial in COPD
Table 4: Trelegy Ellipta sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 5: Trelegy Ellipta drug profile
Table 6: Trelegy Ellipta Phase III trials in asthma
Table 7: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll